论文部分内容阅读
本文应用逆转录聚合酶链反应（ＲＴ—ＰＣＲ）技术检测急性淋巴细胞白血病（ＡＬＬ）２０例，慢性淋巴细胞白血病（ＣＬＬ）８例，多发性骨髓瘤（ＭＭ）１７例等肿瘤细胞多药耐药（ＭＤＲ１）基因的表达，其中初治２８例，难治复发６例，完全缓解（ＣＲ）１１例。发现ＭＤＲ１基因在ＡＬＬ、ＣＬＬ及ＭＭ中表达阳性率分别为３５．７％，８３．３％及９％。难治复发组明显高于初治及ＣＲ组，三者比较差异显著（Ｐ＜０．０１）。初治ＭＤＲ１基因阴性表达组ＣＲ率（９４．４％）显著低于ＭＤＲ１基因阳性表达组（３０％）（Ｐ＜０．０１）。其结果表明：①淋巴—浆细胞系统恶性肿瘤细胞中ＭＤＲ１发生有原发性和继发性两种形式，其中ＭＭ发生率较低。②淋巴—浆细胞系统恶性肿瘤患者ＭＤＲ１基因表达与肿瘤细胞多药耐药性密切相关，可为临床合理制定化疗方案提供有用的依据。
In this article, we used reverse transcription polymerase chain reaction (RT-PCR) technology to detect multidrug resistance in 20 cases of acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) in 8 cases, and multiple myeloma (MM) in 17 cases. Drug (MDR1) gene expression, including 28 cases of initial treatment, refractory relapse in 6 cases, 11 cases of complete remission (CR). The positive rates of MDR1 gene expression in ALL, CLL and MM were 35.7%, 83.3% and 9%, respectively. The relapsed group was significantly higher than the untreated and CR group, and the difference between the three groups was significant (P<0.01). The CR rate (94.4%) was significantly lower in the newly diagnosed MDR1 gene expression group than in the MDR1 gene positive expression group (30%) (P<0.01). The results showed that: 1) The primary and secondary forms of MDR1 in lymphoid-plasma system malignant tumor cells occurred, and the incidence of MM was low. 2MDR1 gene expression in patients with lymphoma-plasma system malignant tumors is closely related to multidrug resistance of tumor cells, which can provide a useful basis for the rational development of chemotherapy programs.